John Sakys insider trades: Mesa Laboratories (MLAB) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where John reports to the SEC
Open-market buys and sales
28 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 22, 2026 | MLAB | ↓ Sell10b5-1 | 2,827 | $89.50 | $253K | Direct | Jun 23, 2026 (1d) |
| Jun 16, 2026 | MLAB | ↓ Sell | 1,223 | $101.27 | $124K | Direct | Jun 17, 2026 (1d) |
| Jun 16, 2025 | MLAB | ↓ Sell | 642 | $97.12 | $62K | Direct | Jun 18, 2025 (2d) |
| Mar 24, 2023 | MLAB | ↓ Sell10b5-1 | 4,628 | $169.50 | $784K | Direct | Mar 27, 2023 (3d) |
| Mar 15, 2023 | MLAB | ↓ Sell10b5-1 | 1,000 | $165.71 | $166K | Direct | Mar 16, 2023 (1d) |
| Mar 9, 2023 | MLAB | ↓ Sell10b5-1 | 400 | $169.97 | $68K | Direct | Mar 9, 2023 (0d) |
| Feb 9, 2023 | MLAB | ↓ Sell10b5-1 | 1,000 | $184.27 | $184K | Direct | Feb 9, 2023 (0d) |
| Jan 23, 2023 | MLAB | ↓ Sell10b5-1 | 2,100 | $210.19 | $441K | Direct | Jan 25, 2023 (2d) |
| Aug 16, 2022 | MLAB | ↓ Sell | 2,000 | $200.57 | $401K | Direct | Aug 17, 2022 (1d) |
| Jun 21, 2022 | MLAB | ↓ Sell | 722 | $188.22 | $136K | Direct | Jun 22, 2022 (1d) |
| Apr 20, 2022 | MLAB | ↓ Sell10b5-1 | 72 | $250.44 | $18K | Direct | Apr 22, 2022 (2d) |
| Mar 24, 2022 | MLAB | ↓ Sell10b5-1 | 1,600 | $251.23 | $402K | Direct | Mar 25, 2022 (1d) |
| Dec 10, 2021 | MLAB | ↓ Sell10b5-1 | 1,758 | $324.74 | $571K | Direct | Dec 10, 2021 (0d) |
| Nov 11, 2021 | MLAB | ↓ Sell | 1,000 | $317.12 | $317K | Direct | Nov 12, 2021 (1d) |
| Oct 20, 2021 | MLAB | ↓ Sell10b5-1 | 2,000 | $309.86 | $620K | Direct | Oct 25, 2021 (5d) |
| Sep 10, 2021 | MLAB | ↓ Sell10b5-1 | 1,400 | $270.21 | $378K | Direct | Sep 10, 2021 (0d) |
| Aug 12, 2021 | MLAB | ↓ Sell10b5-1 | 1,000 | $275.16 | $275K | Direct | Aug 13, 2021 (1d) |
| Jul 12, 2021 | MLAB | ↓ Sell10b5-1 | 1,000 | $278.77 | $279K | Direct | Jul 13, 2021 (1d) |
| Jul 1, 2021 | MLAB | ↓ Sell | 1,000 | $267.04 | $267K | Direct | Jul 6, 2021 (5d) |
| Jun 16, 2021 | MLAB | ↓ Sell | 2,119 | $255.67 | $542K | Direct | Jun 17, 2021 (1d) |
| Mar 12, 2021 | MLAB | ↓ Sell | 2,500 | $263.84 | $660K | Direct | Mar 15, 2021 (3d) |
| Jan 6, 2021 | MLAB | ↓ Sell | 16 | $290.00 | $5K | Direct | Jan 7, 2021 (1d) |
| Nov 17, 2020 | MLAB | ↓ Sell | 984 | $290.00 | $285K | Direct | Nov 18, 2020 (1d) |
| Oct 8, 2020 | MLAB | ↓ Sell | 942 | $276.90 | $261K | Direct | Oct 9, 2020 (1d) |
| Sep 2, 2020 | MLAB | ↓ Sell | 1,000 | $251.00 | $251K | Direct | Sep 4, 2020 (2d) |
| Aug 14, 2020 | MLAB | ↓ Sell | 1,000 | $244.00 | $244K | Direct | Aug 17, 2020 (3d) |
| Aug 15, 2018 | MLAB | ↓ Sell | 1,000 | $203.50 | $204K | Direct | Aug 15, 2018 (0d) |
| Nov 17, 2016 | MLAB | ↓ Sell | 1,000 | $127.14 | $127K | Direct | Nov 17, 2016 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other MLAB insiders
Open-market trades in the last 12 months
About John Sakys's insider trades
John Sakys is CFO at Mesa Laboratories (MLAB). Since Nov 17, 2016, John has reported no open-market purchases and 28 sales worth $8.3M on SEC Form 4. In the last 12 months: 2 sales ($377K).
13 sales (53% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include option exercises (40 filings), grants and awards (23 filings), shares withheld for taxes (9 filings), other transactions (6 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every MLAB insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.